Sequoia Financial Advisors LLC Lowers Holdings in Hologic, Inc. (NASDAQ:HOLX)

Sequoia Financial Advisors LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 25.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,279 shares of the medical equipment provider’s stock after selling 2,189 shares during the period. Sequoia Financial Advisors LLC’s holdings in Hologic were worth $388,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 400 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Hologic in the fourth quarter worth about $49,000. Finally, West Financial Advisors LLC purchased a new stake in shares of Hologic in the first quarter worth about $50,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director directly owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HOLX shares. Raymond James Financial reiterated an “outperform” rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Evercore ISI reduced their price objective on Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Stephens reduced their price objective on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 13th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $77.42.

Hologic Trading Down 0.0%

Shares of NASDAQ HOLX opened at $65.30 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The business’s 50 day moving average price is $60.45 and its 200-day moving average price is $63.86. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a market cap of $14.55 billion, a price-to-earnings ratio of 27.55, a PEG ratio of 2.39 and a beta of 0.55.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business posted $1.03 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.